Type II variation submitted to the European Medicines Agency to expand current VELCADE® label to include previously untreated patients with Mantle Cell Lymphoma June 27, 2014 …
VELCADE® Data at EHA 2014 Highlight Efficacy in Newly-Diagnosed Mantle Cell Lymphoma and Reinforce Its Role as a Backbone of Multiple Myeloma Therapy
June 15, 2014 Janssen-Cilag International NV today announced Phase III study data demonstrating that the investigational use of a VELCADE® (bortezomib)-based combination in the treatment …
Phase 3 Data Highlight Benefits of Using VELCADE® within Frontline Treatment of Mantle Cell Lymphoma, with Results Showing Significantly Longer Progression-Free Survival Compared to Standard of Care
Investigational study reports potential benefits of VELCADE (bortezomib)-based combination therapy when used as an initial treatment in this rare blood cancer June 1, 2014 Janssen-Cilag …